Progression of liver fibrosis in HCV‐positive liver transplant recipients randomized to everolimus with reduced calcineurin inhibitor (CNI) therapy or a standard CNI regimen

Publisher： John Wiley & Sons Inc

E-ISSN： 1432-2277|28|3|373-374

ISSN： 0934-0874

Source： TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol.28, Iss.3, 2015-03, pp. : 373-374

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 28, Iss. 5, 2015-05 ,pp. : 553-564

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients – a three‐yr serial echocardiographic substudy of the randomized controlled CENTRAL trial

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 8, 2015-08 ,pp. : 678-684

John Wiley & Sons Inc

Access to resources Recommend Favorite

Protein Kinase C Inhibitor Sotrastaurin in De Novo Liver Transplant Recipients: A Randomized Phase II Trial

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 15, Iss. 5, 2015-05 ,pp. : 1283-1292

John Wiley & Sons Inc

Access to resources Recommend Favorite

Longterm calcineurin inhibitor therapy and brain function in patients after liver transplantation

By  

LIVER TRANSPLANTATION, Vol. 24, Iss. 1, 2018-01 ,pp. : 56-66

John Wiley & Sons Inc

Access to resources Recommend Favorite

Boceprevir in liver transplant recipients

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 1, 2015-01 ,pp. : 192-197

John Wiley & Sons Inc

Access to resources Recommend Favorite